Coverage
-
February 27, 2019
Teva Pharmaceuticals' closely watched challenge to the U.S. Food and Drug Administration's new policy on generic-drug exclusivity is premature because the company may have forfeited exclusivity under other policies, a D.C. federal judge ruled Tuesday.
2 other articles on this case.
View all »